Tufts CSDD Benchmarking Study, Commissioned by Syneos Health, Links Clinical Sourcing Models to Trial Performance and Quality
核心洞察
New benchmarking research from the Tufts Center for the Study of Drug Development (搜索), sponsored and commissioned by Syneos Health, examines how clinical sourcing models relate to trial performance and quality.
A Syneos Health white paper, Drug Development That Moves at the Speed of Change, builds on that research to consider what clinical development must become next.
The white paper outlines four connected dimensions of adaptive drug development: continuous evidence generation, more responsive regulatory engagement, combined AI, data and human expertise, and flexible operating models.
New benchmarking research from the Tufts Center for the Study of Drug Development (搜索) (Tufts CSDD), sponsored and commissioned by Syneos Health, examines how clinical sourcing models relate to trial performance and quality, according to the company. The findings form the evidentiary basis for a Syneos Health white paper, Drug Development That Moves at the Speed of Change, which looks beyond current operating models to consider what clinical development must become next.
Four Dimensions of Adaptive Development
The white paper explores four connected dimensions of adaptive drug development. These comprise continuous evidence generation, more responsive regulatory engagement, the combined power of AI, data and human expertise, and flexible operating models that can evolve with portfolio needs.
According to Syneos Health, these elements together create an environment in which trial design, evidence strategy, technology and execution continuously inform one another, rather than operating as separate, sequential workstreams.
Sourcing Models and Trial Quality
The Tufts CSDD benchmarking research, described by Syneos Health as building on questions raised by the study, focuses specifically on the relationship between clinical sourcing models and trial performance and quality. The company positions the work as a starting point for a broader discussion of how sponsors should structure development operations as science becomes increasingly complex and development ecosystems continue to evolve.
Syneos Health states that sponsors need partners who can simplify complexity, adapt at scale and help accelerate the delivery of life-changing therapies.
Operational Priorities: Site and Patient Burden
The company describes its approach as combining clinical expertise, advanced technology and scalable delivery across the development lifecycle. Stated priorities include designing fit-for-purpose delivery models, reducing site and patient burden, and applying intelligent technologies intended to improve predictability, trial execution and decision-making.
Syneos Health frames these capabilities as a means of helping sponsors navigate change and, in its words, transform complexity into competitive advantage.
DPHARM 2026 Sessions
Syneos Health will present its perspectives at DPHARM 2026, where its team will be available at booth #101 and on stage. The featured program includes a fireside chat, "Navigating Future-Forward Drug Development: Benchmarking Today," scheduled for September 16 from 9:10 to 9:25 a.m., followed by a panel, "Navigating Future-Forward Drug Development: Charting Tomorrow," from 9:25 to 9:55 a.m.
A separate session, "The Hidden Cost of Control: Rethinking Oversight in Clinical Development," is scheduled for September 16 from 3:45 to 4:05 p.m. The company says it will share practical insights and strategies for sponsors exploring new operating models, seeking to improve trial performance, or preparing for what comes next in clinical development.